Condition
Non-Small Cell Lung Cancer With EGFR Mutation
Total Trials
6
Recruiting
3
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
6Total
P 1 (3)
P 2 (2)
P 3 (1)
Trial Status
Recruiting3
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05852990Phase 3RecruitingPrimary
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
NCT04824079Phase 2CompletedPrimary
Keynatinib in Treated Patients With NSCLC and Brain Metastases
NCT06668103Phase 2RecruitingPrimary
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
NCT06641609Phase 1Not Yet RecruitingPrimary
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
NCT04770688Phase 1CompletedPrimary
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
NCT06306456Phase 1RecruitingPrimary
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
Showing all 6 trials